Off-label Use of Secukinumab: A Potential Therapeutic Option for SAPHO Syndrome

J Rheumatol. 2022 Jun;49(6):656. doi: 10.3899/jrheum.211155. Epub 2021 Dec 15.

Authors

Gang Wang¹, Ning Zhuo², Jingyang Li³

Affiliations

¹ Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Zhuzhou.
² Department of Nephrology, Xiangya Second Hospital, Central South University, Changsha, Hunan, China.
³ Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Zhuzhou; wgzncsu@csu.edu.cn.

PMID: 34911808
DOI: 10.3899/jrheum.211155

No abstract available

Publication types

Comment

MeSH terms

Acne Vulgaris*
Acquired Hyperostosis Syndrome* / drug therapy
Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Off-Label Use
Osteitis* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
secukinumab